Breaking Health News: FDA Approvals, Recalls, and Emerging Treatments

The latest health news includes the FDA's approval of a nasal spray alternative to EpiPen for allergic reactions, Perrigo's recall of its infant formula, and France's extended bluetongue vaccination campaign. Also covered are the challenges faced by developers of vapes for migraines and asthma, the FDA's declination to approve an MDMA-based PTSD treatment, Michigan's human swine flu case, and the FDA's extended review of Humacyte's blood vessel implant.

The U.S. Food and Drug Administration has granted approval for ARS Pharmaceuticals' needle-free nasal spray, neffy, as an alternative emergency treatment for severe allergic reactions. This new spray offers an option to the commonly used EpiPen.

In a regulatory filing, Perrigo announced a voluntary recall of 16,500 cans of infant formula sold at H-E-B and CVS. This recall affects three lots within one batch.

Following new outbreaks of the bluetongue virus in ruminants, France's farm ministry has accelerated and expanded its vaccination efforts. The first outbreak was reported on a sheep farm close to the Belgian border.

North American companies pioneering vape-like devices for migraines and asthma face significant hurdles in gaining acceptance from healthcare authorities and patients.

The FDA has declined to approve the first MDMA-based therapy for PTSD, citing insufficient data provided by Lykos Therapeutics.

The Michigan Department of Health and Human Services has identified a human case of swine flu, with the source of exposure currently under investigation.

Humacyte announced that the FDA has extended its review period for a new blood vessel implant, impacting the company's stock negatively.

(With inputs from agencies.)